Expanding access to cancer immunotherapy: A systematic review of low-dose PD-(L)1 inhibitor strategies.

Background: Anti-PD-(L)1 inhibitors have transformed cancer treatment. However, their high costs severely restrict their accessibility, especially in low- and middle-income countries (LMIC). Low-dose regimens, inferior to weigh-based or flat dosings, may help address this barrier.